European Heart Journal

Article	Citations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	6739
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice	3119
2021 ESC/EACTS Guidelines for the management of valvular heart disease	2660
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	1510
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	1113
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio	1046
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy	1024
2023 ESC Guidelines for the management of acute coronary syndromes	933
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe	626
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases	582
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	546
2023 ESC Guidelines for the management of cardiomyopathies	512
European Society of Cardiology: cardiovascular disease statistics 2021	496
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis	463
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement	452
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery	437
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research	425
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather	396
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus	376
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes	346
2023 ESC Guidelines for the management of endocarditis	345
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force	318
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance	288
C-reactive protein and clinical outcomes in patients with COVID-19	277
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement	268

SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions	268
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study	221
Left bundle branch area pacing outcomes: the multicentre European MELOS study	220
Prevalence of statin intolerance: a meta-analysis	216
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o	213
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies	199
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study	197
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement	189
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials	186
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	185
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy	176
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists	172
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction	166
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis	166
Heart failure drug treatment: the fantastic four	157
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study	156
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies	151
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism	151
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction	151
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults	149
Empagliflozin in acute myocardial infarction: the EMMY trial	148
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial	147
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank	147
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery	147
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials	144
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank	143
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial	139
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial	136
Application of artificial intelligence to the electrocardiogram	135
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF	135
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)	134
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes	131
Mendelian randomization for cardiovascular diseases: principles and applications	129
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis	127
Electrocardiogram screening for aortic valve stenosis using artificial intelligence	124
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme	123
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial	123
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk	122
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study	118
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial	115
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis	114
Colchicine and the heart	112
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality	107
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s	105
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials	105
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study	104
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk	104
Combination lipid-lowering therapy as first-line strategy in very high-risk patients	104
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials	103
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial	102

Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial	101
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease	101
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study	100
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study	100
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial	99
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)	98
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial	98
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group	97
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry	96
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations	95
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial	95
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th	95
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial	94
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction	94
Sex differences in arterial hypertension	93
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome	92
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study	92
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy	92
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction	92
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up	92
High-density lipoprotein revisited: biological functions and clinical relevance	92
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes	91
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis	90
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial	90
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy	90
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation	89
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA	88
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme	88
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis	87
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta	87
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications	87
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo	86
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance	85
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction	85
Targeting the CCL2–CCR2 axis for atheroprotection	84
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms	83
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis	83
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial	83
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial	82
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study	82
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection	81
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He	81
The dawn of a new era of targeted lipid-lowering therapies	81
Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up	80
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models	79
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction	79
The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease	78
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial	78
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data	77
Road traffic noise and cardiovascular disease risk factors in UK Biobank	76
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome	75
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis	75
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy	75
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data	75
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy	75
SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe	74
Iron deficiency and cardiovascular disease	74
Effects of canagliflozin on human myocardial redox signalling: clinical implications	73
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study	73
Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease	73
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death	72
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases	72
Anthropometric measures and adverse outcomes in heart failure with reduced ejection fraction: revisiting the obesity paradox	72
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study	72
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score	71
Restrictive cardiomyopathy: definition and diagnosis	70
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole	70
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventio	70
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease	70
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis	70
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality	70
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study	69
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications	69
Vigorous physical activity, incident heart disease, and cancer: how little is enough?	69
Heart healthy cities: genetics loads the gun but the environment pulls the trigger	68
Elevated remnant cholesterol, plasma triglycerides, and cardiovascular and non-cardiovascular mortality	68
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study	68
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis	67
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences	66
Fractional flow reserve versus angiography-guided strategy in acute myocardial infarction with multivessel disease: a randomized trial	66

Brugada syndrome genetics is associated with phenotype severity	66
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR	66
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction	65
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis	65
Dapagliflozin for heart failure according to body mass index: the DELIVER trial	65
Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (A	64
Modifiable risk factors associated with cardiovascular disease and mortality in China: a PURE substudy	64
A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study	64
Targeted proteomics improves cardiovascular risk prediction in secondary prevention	64
The struggle towards a Universal Definition of Heart Failure—how to proceed?	63
Exercise benefits in cardiovascular diseases: from mechanisms to clinical implementation	63
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial	63
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank	63
Artificial intelligence in the diagnosis and management of arrhythmias	62
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction	62
Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm	62
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled	61
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey	61
Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women	61
Hypertension management in patients with cardiovascular comorbidities	61
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?	61
Trends in survival after cardiac arrest: a Swedish nationwide study over 30 years	61
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study	61
Cardiac sarcoidosis: phenotypes, diagnosis, treatment, and prognosis	60
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry	60
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis	60
Association of the combined effects of air pollution and changes in physical activity with cardiovascular disease in young adults	59
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s	59
Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis	59
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs	59
Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial	58
Silent brain infarcts impact on cognitive function in atrial fibrillation	58
Accelerated and personalized therapy for heart failure with reduced ejection fraction	58
Prognostic value of stress echocardiography assessed by the ABCDE protocol	57
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome	56
Smoking cessation, but not reduction, reduces cardiovascular disease incidence	56
Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective	56
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study	56
Automated external defibrillators delivered by drones to patients with suspected out-of-hospital cardiac arrest	56
Extracellular vesicles from immortalized cardiosphere-derived cells attenuate arrhythmogenic cardiomyopathy in desmoglein-2 mutant mice	56
SGLT2 inhibitors: the statins of the 21st century	56
Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke	55
Ultra-processed food intake and all-cause and cause-specific mortality in individuals with cardiovascular disease: the Moli-sani Study	55
Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study	55
Predictors of mortality in thrombotic thrombocytopenia after adenoviral COVID-19 vaccination: the FAPIC score	55
Macrophage NFATc3 prevents foam cell formation and atherosclerosis: evidence and mechanisms	55
Lipoprotein(a) is associated with the onset but not the progression of aortic valve calcification	55
Cardiovascular disease, mortality, and their associations with modifiable risk factors in a multi-national South Asia cohort: a PURE substudy	54
Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy	54
Sodium intake, life expectancy, and all-cause mortality	54
Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial	54
Cardiovascular magnetic resonance in light-chain amyloidosis to guide treatment	54
Tilt testing remains a valuable asset	54
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA	54
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial	54
Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23	53
Subcutaneous implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study	53
Impact of sex on the management and outcome of aortic stenosis patients	53
Accelerometer-derived physical activity and risk of atrial fibrillation	53
Which patients with aortic stenosis should be referred to surgery rather than transcatheter aortic valve implantation?	53
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials	53
A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity	53
Nomenclature for kidney function and disease—executive summary and glossary from a Kidney Disease: Improving Global Outcomes (KDIGO) consensus conference	52
Pathogenesis and management of abdominal aortic aneurysm	52
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study	52
Atrial septal defect in adulthood: a new paradigm for congenital heart disease	52
Reduction of environmental pollutants for prevention of cardiovascular disease: it’s time to act	52
The ‘Ten Commandments’ of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	52
Corrigendum to: 2021 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (	51
Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis	51
Immune complexes, innate immunity, and NETosis in ChAdOx1 vaccine-induced thrombocytopenia	51
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies	51
Hypertension in children and adolescents	50
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study	50
Importance of genotype for risk stratification in arrhythmogenic right ventricular cardiomyopathy using the 2019 ARVC risk calculator	50
Determinants of outcomes following surgery for type A acute aortic dissection: the UK National Adult Cardiac Surgical Audit	50
Peripartum cardiomyopathy: from genetics to management	50
A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy	50
Lipoprotein(a) is associated with large artery atherosclerosis stroke aetiology and stroke recurrence among patients below the age of 60 years: results from the BIOSIGNAL study	49
Economic burden of cardiovascular diseases in the European Union: a population-based cost study	49
Statin associated lower cancer risk and related mortality in patients with heart failure	49
Physical activity volume, intensity, and incident cardiovascular disease	49
Physical activity and fitness in the community: the Framingham Heart Study	49
Functionally validated SCN5A variants allow interpretation of pathogenicity and prediction of lethal events in Brugada syndrome	48
Right ventricle assessment in patients with pulmonary embolism at low risk for death based on clinical models: an individual patient data meta-analysis	48
Ventricular arrhythmia burden during the coronavirus disease 2019 (COVID-19) pandemic	47
Current use and safety of novel oral anticoagulants in adults with congenital heart disease: results of a nationwide analysis including more than 44 000 patients	47
Chronic venous insufficiency, cardiovascular disease, and mortality: a population study	47
Cardiac rehabilitation for heart failure: ‘Cinderella’ or evidence-based pillar of care?	47
Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity	46
Triglyceride-rich lipoprotein remnants, low-density lipoproteins, and risk of coronary heart disease: a UK Biobank study	46
Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis	46
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials	46
The collateral damage of COVID-19 to cardiovascular services: a meta-analysis	46
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy	46